After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Rigel (RIGL)Zacks Investment Research • 10/14/25
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDSPRNewsWire • 10/08/25
Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?Zacks Investment Research • 09/29/25
Rigel (RIGL) Loses 27.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 09/26/25
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?Zacks Investment Research • 09/25/25
Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock?Zacks Investment Research • 09/18/25
What Makes Rigel Pharmaceuticals (RIGL) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 09/09/25
Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out?Zacks Investment Research • 08/25/25
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy?Zacks Investment Research • 08/07/25
Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run?Zacks Investment Research • 08/07/25
Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass EstimatesZacks Investment Research • 08/05/25
Rigel Reports Second Quarter 2025 Financial Results and Provides Business UpdatePRNewsWire • 08/05/25
Can Rigel (RIGL) Climb 69.55% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 07/30/25
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business UpdatePRNewsWire • 07/29/25